5-benzo[1.3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde | 871516-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 5-benzo[1.3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde
• 英文别名: 5-(2H-1,3-Benzodioxol-5-yl)-1-methyl-1H-imidazole-2-carbaldehyde；5-(1,3-benzodioxol-5-yl)-1-methylimidazole-2-carbaldehyde
• CAS: 871516-83-5
• 化学式: C₁₂H₁₀N₂O₃
• 分子量: 230.223
• InChiKey: CFRSQTYLBIFGCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-benzo[1.3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde 在 哌啶 、 三溴化硼 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 18.5h， 生成 2-[[5-(3,4-Dihydroxyphenyl)-1-methylimidazol-2-yl]methylidene]propanedioic acid
  参考文献：
  名称：

  Functional derivatives of 5-benzo[1,3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde and evaluation of leishmanicidal activity

  摘要：

  New imidazole derivatives were obtained after subjecting 5-benzol[1,3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde to a Knoevenagel reaction. Some of these compounds exhibit significant in vitro leishmanicidal activity. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00106-9
• 作为产物：
  描述：

  5-(methyliminomethyl)-1,3-benzodioxole 在 正丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 49.5h， 生成 5-benzo[1.3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde
  参考文献：
  名称：

  Functional derivatives of 5-benzo[1,3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde and evaluation of leishmanicidal activity

  摘要：

  New imidazole derivatives were obtained after subjecting 5-benzol[1,3]dioxol-5-yl-1-methyl-1H-imidazole-2-carbaldehyde to a Knoevenagel reaction. Some of these compounds exhibit significant in vitro leishmanicidal activity. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00106-9

文献信息

• [EN] SUBSTITUTED PYRROLIDINE-2-ONES<br/>[FR] PYRROLIDINE-2-ONES SUBSTITUEES
  申请人：NOVARTIS AG

  公开号：WO2005118535A1

  公开（公告）日：2005-12-15

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, to processes for their manufacture, to their use as pharmaceuticals, in diagnosis, as PET ligands and to pharmaceutical or diagnostic compositions comprising such compounds.

  这项发明涉及到式(I)中R1、R2、R3、R4和n的化合物，其中这些参数在规范中有定义，以及它们的制造过程，作为药物的用途，在诊断中作为PET配体，以及包含这些化合物的药物或诊断组合物。
• Substituted pyrrolidine-2-ones
  申请人：Muller Werner

  公开号：US20070172421A1

  公开（公告）日：2007-07-26

  The invention relates to compounds of formula (I) Wherein R 1 , R 2 , R 3 , R 4 and n are as defined in the specification, to processes for their manufacture, to their use as pharmaceuticals, in diagnosis, as PET ligands and to pharmaceutical or diagnostic compositions comprising such compounds.

  本发明涉及化合物(I)的公式，其中R1、R2、R3、R4和n如规范所定义，以及它们的制造方法，它们作为药物的用途，在诊断中作为PET配体以及包含这些化合物的药物或诊断组合物。
• NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Giese Armin

  公开号：US20110293520A1

  公开（公告）日：2011-12-01

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R 1 )(R 2 )—, —C(R 3 )═, —N(R 4 )—, —N═, —N + (R 5 )═, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).

  本发明涉及一种由公式（E）表示的化合物。本发明还涉及一种由公式（E）表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病相关的疾病。此外，本发明涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备可检测标记的本发明化合物的试剂盒。公式（E）中，X、Y和L分别独立地从—C（R1）（R2）—、—C（R3）═、—N（R4）—、—N═、—N+（R5）═、—O—和—S—中非定向选择；M和Z分别独立地从公式（I）和公式（II）中非定向选择。
• DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Ludwig-Maximilians-Universität München

  公开号：US20160185730A1

  公开（公告）日：2016-06-30

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式(E)所表示的化合物。本发明还涉及一种由式(E)所表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病有关的疾病。此外，本发明还涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备本发明化合物的可检测标记试剂盒。
• Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2687513A1

  公开（公告）日：2014-01-22

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。